Silence Therapeutics plc (NASDAQ:SLN) stock is trading higher on Monday after the company reported positive topline outcomes from its Phase 2 SANRECO study assessing divesiran for polycythemia vera. It is a rare, slow-growing blood cancer where the bone marrow makes too many red blood cells.
The extra production thickens the blood, slows down blood flow, and raises the risk of dangerous blood clots, heart attacks, and strokes.
The mid-stage trial successfully met both its primary and key secondary metrics, demonstrating strong efficacy alongside a favorable safety profile in phlebotomy-dependent trial participants.
“The SANRECO Phase 2 trial delivered our best-case outcome, confirming the impressive results observed in Phase 1 with dosing every six weeks and demonstrating equally robust and durable effects with quarterly dosing,” said Curtis Rambaran, Chief Medical Officer at Silence.
SANRECO Study Meets Primary Efficacy Endpoints
The 36-week trial evaluated divesiran, a first-in-class short interfering RNA therapy, across 48 patients receiving a 6 mg/kg subcutaneous dose every six or twelve weeks.
Overall, 88% of divesiran-treated patients achieved the primary endpoint—defined as the absence of phlebotomies while maintaining hematocrit levels below 45% between weeks 18 and 36—compared to just 19% of placebo recipients.
Dosing schedules administered every six weeks and every twelve weeks demonstrated response rates of 93.8% and 81.3%, respectively, yielding a placebo-adjusted response rate of 69%.
Secondary Outcomes And Tolerability Profile
The clinical trial also achieved key secondary endpoints during the 36-week timeframe.
Divesiran significantly decreased phlebotomy (vein puncturing) requirements, with treated subjects averaging 0.2 phlebotomies compared to 2.1 procedures in the placebo arm.
Participants receiving divesiran also showed enhancements in hematocrit management, iron ferritin markers, and symptom reductions recorded through the MPN-SAF Total Symptom Score.
Divesiran was well tolerated throughout the study, showing safety results consistent with earlier clinical evaluations.
No new safety concerns emerged, and reported injection site reactions were infrequent and self-limiting.
Two investigator-reported grade 1 anemia adverse events occurred. Based on these results, a Phase 3 trial comparing twelve-week divesiran administration to placebo is expected to launch in the first half of 2027.
The company reported a cash balance of $72.1 million as of June 30, 2026.
SLN Price Action: Silence Therapeutics shares were up 36.82% at $16.35 at the time of publication on Monday. The stock is trading at a new 52-week high, according to Benzinga Pro data.
Image via Shutterstock/ Yomal2233
Login to comment